波音游戏-波音娱乐城赌球打不开

Beneficiaries

22 Dec 2019

Safeguarding well-being through biomedical science - Named Professorship Scheme promotes excellence in research

Technological innovation holds great promise for the medical field, and one of the top scientists at CityUHK is dedicated to bridging these two domains.

Professor Michael Yang Mengsu

Yeung Kin Man Chair Professor of Biomedical Sciences
Senior Vice-President (Innovation and Enterprise)
Director (Tung Biomedical Sciences Centre)
Director (Biotechnology & Health Centre)

Full Story

Professor Michael Yang Mengsu, Yeung Kin Man Chair Professor of Biomedical Sciences, is seeking to improve people’s lives by converting his research into clinical applications.

“The ultimate goal of biomedical research is to contribute to human well-being. We hope to encourage more students to find and develop their passions for research and innovation and cultivate an entrepreneurial mindset for the challenge of converting CityUHK’s many high-quality research projects into clinical applications that benefit society,” Professor Yang said.

Professor Yang’s research activities focus on the study of the biological processes involved in cancer and the development of biochip technology and nanotechnology for molecular diagnostics and therapeutic applications. He has published more than 200 peer-reviewed papers, received 30 US / China patents and co-founded three spin-off biotech companies since joining CityUHK in 1994. He was awarded the Chunhui Scholar Award by the Ministry of Education in China in 2003, the K. C. Wong Foundation Award in 2004, the Shenzhen Science and Technology Innovation Award in 2006, the Hong Kong Technological Achievement Grand Award in 2007, the Natural Science Award by the Ministry of Education in 2015, and the Wuxi AppTech Life Science and Chemistry Award in 2016.

His latest work won a Gold Medal for a microfluidicsbased technology platform for disease diagnosis and drug screening at the 47th International Exhibition of Invention of Geneva in Switzerland in April 2019. The microfluidic chips can be used for the sensitive detection of multiple gene mutations on barcoded microbead arrays.

This process enables the early identification of infectious pathogens and tumour cells. The platform can also be used to generate arrays of single cells and tumour spheroids for screening the most efficient anti-cancer drugs with their optimal dosages. The patented technology has been licensed to a CityUHK spin-off company that was co-founded recently by three PhD students who graduated from Professor Yang’s laboratory.

Microfluidics Array Technology with Nano-Amplification for Drug Screening and Molecular Diagnosis
“Microfluidics Array Technology with Nano-Amplification for Drug Screening and Molecular Diagnosis”, developed by a research team led by Professor Michael Yang Mengsu.

 

Professor Yang has already turned several research projects into clinical applications. His group previously developed DNA chip technology for the early detection of cervical cancer. That application has been commercialised by a Shenzhen-based company co-founded in 2004 by one of his PhD graduates. Millions of women have benefited from the breakthrough. In addition, a company he helped establish with a PhD graduate and a post-doctoral fellow in Hong Kong in 2010 provides pharmacogenomics and assessment services for side effects from drugs and then suggests relevant preventive measures.

He thanked Dr Yeung Kin-man for supporting the Named Professorship Scheme. With the support of donors, this new scheme aims to promote excellence in research and professional education in the University’s distinguished research areas.

Dr and Mrs Yeung Kin-man
Dr and Mrs Yeung Kin-man at the donation ceremony in 2015. Dr Yeung’s donation supports University’s strategic developments and is used to establish Yeung Kin-man Chair Professorships in the University’s distinguished areas. In addition to biomedical sciences, the areas include
finance, IT innovation and management, media art and neuroscience.

 

These areas include architecture, behavioural and policy sciences, biomedical sciences, data science, data engineering, energy and environment, engineering, environmental veterinary medicine, finance, international economics, information engineering, IT innovation and management, media art, nanomaterials, neuroscience, nuclear engineering, translational neuroscience, and One Health.

“Donations have enabled my students and me to carry out pioneering biomedical research and innovations. We will continue to work hard to develop new technologies that benefit more and more people,” he said.

Research in CityUHK Biomedical Sciences brings new hope and opportunities


In addition to Professor Yang’s efforts to improve people’s lives by converting his research into clinical applications, faculty in CityUHK’s Department of Biomedical Sciences are dedicated to contributing to human betterment through their pioneering research. Associate Professor Dr Yao Xi developed a world-first, self-healable, anti-smudge coating, which enhances medical and aerospace equipment (details); Assistant Professor Dr Chow Kwan-ting studied rare cells that provide insights into developing cancer immunotherapy (details); and Assistant Professor Dr Ban Ki-won developed the first dual stem cell therapy for cardiac repair (details). These research achievements in biomedical science bring new hope and promise new opportunities for safeguarding human well-being.

百家乐网上赌局| 24山向内什么山向最好| 安阳百家乐官网赌博| 大发888 dafa888| 优博百家乐官网现金网| 24山风水水口| 百家乐破解方法技巧| 百家乐象棋赌博| 百家乐单打| 至尊百家乐官网娱乐场| 百家乐足球投注网哪个平台网址测速最好 | 大发888官方下| 现金百家乐官网赢钱| 伯爵百家乐官网娱乐场| 百家乐小型抽水泵| r百家乐官网娱乐下载| 大发888娱乐场 17| 百家乐赌博规| 三公百家乐玩法| 百家乐官网币| 百家乐赌博代理| 摩纳哥百家乐的玩法技巧和规则| 伟易博百家乐官网娱乐城 | 网上百家乐官网娱乐平台| 网上百家乐哪家较安全| 全球最大赌博网站| 百家乐官网路单生| 皇冠现金网信誉| 运城百家乐蓝盾| 网上百家乐官网公式| 百家乐官网群博乐吧blb8v| 利来百家乐官网的玩法技巧和规则 | 高楼24层风水好吗| 沈阳棋牌网| 百家乐开户最快的平台是哪家| 免费百家乐官网预测工具| 百家乐官网稳定打法| 大发8888娱乐城 真钱| 银泰百家乐龙虎斗| 百家乐技术方式| 百家乐平注法到6|